Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: Preclinical Parkinson disease

Journal of Neural Transmission

Volumn 118, Issue 5, 2011, Pages 821-839

  Ferrer, Isidre ^a   Martinez, Anna ^a   Blanco, Rosa ^a   Dalfó, Ester ^a   Carmona, Margarita ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Cerebral cortex; Endoplasmic reticulum stress; Glycolysis; Haemoglobin; Incidental Lewy body disease; Mitochondria; Olfaction; Oxidative stress; Preclinical Parkinson disease; Striatum; Synuclein

Indexed keywords

ADENOSINE A2 RECEPTOR; ALPHA SYNUCLEIN; BETA SYNUCLEIN; CANNABINOID 1 RECEPTOR; CASEIN KINASE II; COPPER ZINC SUPEROXIDE DISMUTASE; CYTOCHROME C OXIDASE; DOCOSAHEXAENOIC ACID; FERRITIN; GLUTATHIONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INITIATION FACTOR 2ALPHA; IRON; LEUCINE ENKEPHALIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; NEUROMELANIN; PEROXIREDOXIN 2; PORIN; PROTEASOME; PROTEIN P62; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SERINE; SYNAPTOPHYSIN; TYROSINE 3 MONOOXYGENASE; UBIQUITIN; UNINDEXED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

AGE; AMINO TERMINAL SEQUENCE; APATHY; ASTROCYTE; AUTOPHAGOSOME; AUTOPHAGY; AUTOPSY; BEHAVIOR CHANGE; BRAIN CORTEX; BRAIN LEVEL; BRAIN OXYGEN CONSUMPTION; CARBOXY TERMINAL SEQUENCE; CAUDATE NUCLEUS; CELL DEATH; CONFOCAL MICROSCOPY; CORPUS STRIATUM; CYTOPLASM; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; DOPAMINERGIC NERVE CELL; ENDOPLASMIC RETICULUM STRESS; ENERGY METABOLISM; EXHAUSTION; FRONTAL CORTEX; GEL ELECTROPHORESIS; GLYCOLYSIS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; IRON METABOLISM; LEWY BODY; LYSOSOME; MASS SPECTROMETRY; MEDULLA OBLONGATA; MICROARRAY ANALYSIS; MITOCHONDRION; NEURITE; NEUROPATHOLOGY; NONHUMAN; OLFACTORY BULB; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARKINSON DISEASE; PARKINSONISM; PEROXIDATION; POSITRON EMISSION TOMOGRAPHY; PRECLINICAL PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; TAUOPATHY; WESTERN BLOTTING;

ALPHA-SYNUCLEIN; CASEIN KINASE II; DISEASE PROGRESSION; ENDOPLASMIC RETICULUM; GUANINE; HUMANS; IRON; MITOCHONDRIAL DISEASES; NERVE TISSUE PROTEINS; NEURONS; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; UBIQUITINATION;

EID: 79956196722     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0482-8     Document Type: Review

References (140)

1. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, Schapira AHV (2010) Chaperone-mediated autophagy markers are abnormal in Parkinson's disease brain. Arch Neurol [Epub ahead of print]
2. JK Andersen 2004 Iron dysregulation and Parkinson's disease J Alzheimers Dis 6 S47 S52 15665414 1:CAS:528:DC%2BD2MXisVOksL8%3D
3. JP Anderson DE Walker JM Goldstein R Laat K Banducci RJ Caccavello R Barbour J Huang K Kling M Lee L Diep PS Keim X Shen T Chartaway MG Schlossmacher P Seubert D Schenk S Sinha WP Gai TJ Chilcote 2006 Phosphorylation of Ser 129 is the dominant pathological modification of synuclein in familial and sporadic Lewy body disease J Biol Chem 281 29739 29759 16847063 1:CAS:528: DC%2BD28XhtVahsb%2FI
4. P Anglade S Vyas F Javoy-Agid MT Herrero PP Michel J Marquez A Mouatt-Prigent M Ruberg EC Hirsch Y Agid 1997 Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease Histol Histopathol 12 25 31 9046040 1:CAS:528:DyaK2sXitlOmtro%3D (Pubitemid 27106916)
5. M Baba S Nakajo PH Tu T Tomita VM Lee JQ Trojanowski T Iwatsubo 1998 Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies Am J Pathol 152 879 884 9546347 1:CAS:528:DyaK1cXivVKgsbc%3D (Pubitemid 28173348)
6. KJ Barnham AI Bush 2008 Metals in Alzheimer's and Parkinson's diseases Curr Opin Chem Biol 12 222 228 18342639 1:CAS:528:DC%2BD1cXlslKlsbY%3D
7. TG Beach CH Adler L Lue LI Sue J Bachalakuri J Henry-Watson J Sasse S Boyer S Shirohi R Brooks J Eschbacher CL White 3rd H Akiyama J Caviness HA Shill DJ Connor MN Sabbagh DG Walker Arizona Parkinson's Disease Consortium 2009 Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction Acta Neuropathol 117 613 634 19399512
8. M Biagioli M Pinto D Cesselli M Zaninello D Lazarevic P Roncaglia R Simone C Vlachouli C Plessy N Bertin A Beltrami K Kobayashi V Gallo C Santoro I Ferrer S Rivella CA Beltrami P Carninci E Raviola S Gustincich 2009 Unexpected expression of alpha- and beta-globin in mesencephalic dopaminergic neurons and glial cells Proc Natl Acad Sci 106 15454 15459 19717439 1:CAS:528: DC%2BD1MXhtFGjur3E
9. A Bloch A Probst H Bissing H Adams M Tolnay 2006 Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects Neuropathol Appl Neurobiol 32 284 295 16640647 1:CAS:528:DC%2BD28XlvVyju78%3D
10. H Braak K del Tredici 2008 Cortico-basal ganglia-cortical circuitry in Parkinson's disease reconsidered Exp Neurol 212 226 229 18501351
11. H Braak D Sandmann-Keil W Gai E Braak 1999 Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry Neurosci Lett 265 67 69 10327208 1:CAS:528:DyaK1MXivF2is7g%3D (Pubitemid 29210200)
12. H Braak K del Tredici H Bratzke J Hamm-Clement D Sandemann-Keil U Rub 2002 Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages) J Neurol 249 suppl 3 1 5
13. H Braak K del Tredici U Rüb RAI de Vos ENH Jansen Steur E Braak 2003 Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 24 197 211 12498954 (Pubitemid 36007810)
14. H Braak E Ghebremedhin U Rüb H Bratzke K del Tredici 2004 Stages in the development of Parkinson's disease-related pathology Cell Tissue Res 318 121 134 15338272 (Pubitemid 39362633)
15. H Braak U Rüb EN Jansen Steur K del Tredici RA de Vos 2005 Cognitive status correlates with neuropathologic state in Parkinson disease Neurology 64 1404 1410 15851731 1:STN:280:DC%2BD2M3hsleruw%3D%3D (Pubitemid 40570509)
16. H Braak CM Muller U Rüb H Ackermann H Bratzke RA de Vos K del Tredici 2006 Pathology associated with sporadic Parkinson's disease: where does it end? J Neural Transm Suppl 70 89 97 17017514 (Pubitemid 44622184)
17. 2a receptor expression levels J Neurochem 112 1273 1285 20002525 1:CAS:528: DC%2BC3cXisVCis74%3D
18. KR Chaudhuri L Yates P Martínez-Martín 2005 The non-motor symptom complex of Parkinson's disease: a comprehensive assessment is essential Curr Neurol Neurosci Rep 5 275 283 15987611 (Pubitemid 41149661)
19. O Chiba-Falek GJ Lopez RL Nussbaum 2006 Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients Mov Disord 21 1703 1708 16795004 (Pubitemid 44742201)
20. SJ Chinta JK Andersen 2008 Redox imbalance in Parkinson's disease Biochem Biophys Acta 1780 1362 1367 18358848 1:CAS:528:DC%2BD1cXhtVartr7O
21. J Choi AI Levey ST Weintraub HD Rees M Gearing LS Chin L Li 2004 Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases J Biol Chem 279 13256 13264 14722078 1:CAS:528:DC%2BD2cXitl2ns7k%3D (Pubitemid 38445905)
22. J Choi HD Rees ST Weintraub AI Levey LS Chin L Li 2005 Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases J Biol Chem 280 11648 11655 15659387 1:CAS:528:DC%2BD2MXisVyjt7Y%3D (Pubitemid 40418479)
23. Y Chu H Dodiya P Aebischer CW Olanow JH Kordower 2009 Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions Neurobiol Dis 35 385 398 19505575 1:CAS:528:DC%2BD1MXpsFyls78%3D
24. KK Chung B Thomas X Li O Pletnikova JC Troncoso L Marsh VL Dawson TM Dawson 2004 S-Nitrosylation of parkin regulates ubiquitination and compromises Parkin's protective function Science 304 1328 1331 15105460 1:CAS:528: DC%2BD2cXkt1Ggu7c%3D (Pubitemid 38697430)
25. AM Cuervo L Stefanis R Fredenburg PT Lansbury D Sulzer 2004 Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy Science 305 1292 1295 15333840 1:CAS:528:DC%2BD2cXmvFCit7w%3D (Pubitemid 39129234)
26. E Dalfó I Ferrer 2008 Early α-synuclein lipoxidation in neocortex in Lewy body diseases Neurobiol Aging 29 408 417 17166629 (Pubitemid 351222679)
27. E Dalfó M Barrachina JL Rosa S Ambrosio I Ferrer 2004 Abnormal α-synuclein interactions with rab3a and rabphilin in diffuse Lewy body disease Neurobiol Dis 16 92 97 15207266 (Pubitemid 38569800)
28. E Dalfó M Portero-Otín V Ayala A Martínez R Pamplona I Ferrer 2005 Evidence of oxidative stress in the neocortex in incidental Lewy body disease J Neuropathol Exp Neurol 64 1 13
29. SE Daniel CH Hawkes 1992 Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology Lancet 340 186 1352606 1:STN:280:DyaK38zis1Gjug%3D%3D
30. K Del Tredici U Rüb RA De Vos JR Bohl H Braak 2002 Where does Parkinson disease pathology begin in the brain? J Neuropathol Exp Neurol 61 413 426 12030260 (Pubitemid 34533671)
31. A DelleDonne KJ Klos H Fujishiro Z Ahmed JE Parisi KA Josephs R Frigerio M Burnett ZK Wszolek RJ Uiti JE Ahlskog DW Dickson 2008 Incidental Lewy body disease and preclinical Parkinson disease Arch Neurol 65 1074 1080 18695057
32. DT Dexter J Sian S Rose JG Hindmarsh VM Mann JM Cooper FR Wells SE Daniel AJ Lees AH Schapira 1994 Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease Ann Neurol 35 38 44 8285590 1:STN:280:DyaK2c7htlGqsw%3D%3D (Pubitemid 24027604)
33. DW Dickson 2001 Alpha-synuclein and the Lewy body disorders Curr Opin Neurol 14 423 432 11470957 1:STN:280:DC%2BD3MvitV2qtg%3D%3D
34. DW Dickson H Fujishiro A DelleDonne J Menke Z Ahmed KJ Klos KA Josephs R Frigerio M Burnett JE Parisi JE Ahlskog 2008 Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease Acta Neuropathol 115 437 444 18264713
35. DW Dickson H Uchikado H Fujishiro Y Tsuboi 2010 Evidence in favor of Braak staging of Parkinson's disease Mov Disord 25 Suppl 1 S78 S82 20187227
36. M Digicaylioglu S Bichet HH Marti RH Wenger LA Rivas C Bauer M Gassmann 1995 Localization of specific erythropoietin binding sites in defined areas of the human brain Proc Natl Acad Sci USA 93 3717 3720
37. KL Double 2006 Functional effects of neuromelanin and synthetic melanin in model systems J Neuarl Transm 113 751 756 1:CAS:528:DC%2BD28XltlGlt7k%3D (Pubitemid 43847168)
38. KL Double GM Halliday 2006 New face of neuromelanin J Neural Transm Suppl 70 119 123 17017518 1:CAS:528:DC%2BD28Xht1WjsrnO (Pubitemid 44622188)
39. JE Duda BI Giasson Q Chen TL Gur HI Hurtig MB Stern SM Gollomp H Ischiropoulos VM Lee JQ Trojanowski 2000 Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies Am J Pathol 157 1439 1445 11073803 1:CAS:528:DC%2BD3cXosFyiu7o%3D
40. Wolters ECh H Braak 2006 Parkinson's disease: pre-motor clinico-pathological correlations J Neural Transm Suppl 70 309 319 (Pubitemid 44622216)
41. S Engelender 2008 Ubiquitination of alpha synuynucelin and autophagy in Parkinson's disease Autophagy 4 372 374 18216494 1:CAS:528:DC%2BD1cXltVKntLk%3D (Pubitemid 351458104)
42. M Fasano B Bergamasco L Lopiano 2006 Modifications of the iron-neuromelanin system in Parkinson's disease J Neurochem 96 909 916 16417570 1:CAS:528:DC%2BD28XivFSqu7w%3D
43. A Fernandez ML de Ceballos S Rose P Jenner CD Marsden 1996 Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease Brain 119 823 830 8673494 (Pubitemid 26237180)
44. I Ferrer 2009 Early involvement of the cerebral cortex in Parkinson's disease: convergence of multiple metabolic defects Progr Neurobiol 88 89 103 1:CAS:528:DC%2BD1MXmsFyksr0%3D
45. I Ferrer 2009 Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease J Bioenerg Biomembr 41 425 431 19798558 1:CAS:528:DC%2BD1MXhtlCnu7zP
46. I Ferrer R Blanco M Carmona B Puig M Barrachina C Gómez S Ambrosio 2001 Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and dementia with Lewy bodies J Neural Transm 108 1383 1396 11810403 1:CAS:528:DC%2BD38Xit1ymtbg%3D (Pubitemid 34020444)
47. LS Forno 1996 Neuropathology of Parkinson's disease J Neuropathol Exp Neurol 55 259 272 8786384 1:STN:280:DyaK283gslyhsw%3D%3D (Pubitemid 26085575)
48. R Frigerio H Fujishiro DM Maraganore KJ Klos A DelleDonne MG Heckman JE Crook KA Josephs JE Parisi BF Boeve DW Dickson JE Ahlskog 2009 Comparison of risk factor profiles in incidental Lewy body disease and Parkinson disease Arch Neurol 66 1114 1119 19752300
49. H Fujiwara M Hasegawa N Dohmae A Kawashima E Masliah MS Goldberg J Shen K Takio T Iwatsubo 2002 α-synuclein is phosphorylated in synucleinopathy lesions Nat Cell Biol 4 160 164 11813001 1:CAS:528:DC%2BD38XhsVKnur4%3D
50. K Fuxe D Marcellino S Genedani L Agnati 2007 Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease Mov Disord 22 1990 2017 17618524
51. M García-Arencibia C García J Fernández-Ruiz 2009 Cannabinoids and Parkinson's disease CNS Neurol Disord Drug Targets 8 432 439 19839934
52. M Gerlach KL Double MB Youdim P Riederer 2006 Potential sources of increased iron in the substantia nigra of parkinsonian patients J Neural Transm Suppl 70 133 142 17017520 1:CAS:528:DC%2BD28Xht1WjsrnI (Pubitemid 44622190)
53. BI Giasson JE Duda IV Murray Q Chen JM Souza HI Hurtig H Ischiropuolos JQ Trojanowski VMY Lee 2000 Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions Science 290 985 989 11062131 1:CAS:528:DC%2BD3cXnvVWkurY%3D
54. M Goedert 2001 Parkinson's disease and other α-synucleinopathies Clin Chem Lab Med 39 308 312 11388653 1:CAS:528:DC%2BD3MXktFOltL0%3D
55. A Gómez I Ferrer 2009 Increased oxidation of certain glycolysis and energy metabolism enzymes in the frontal cortex in Lewy body diseases J Neurosci Res 87 1002 1013 18855937
56. GM Halliday A Ophof M Broe PH Jensen E Kettle H Fedorow MI Cartwright FM Griffiths CE Shepherd KL Double 2005 Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease Brain 128 2654 2664 16000336 (Pubitemid 41552949)
57. M Hashimoto E Masliah 1999 α-synuclein in Lewy body disease and Alzheimer's disease Brain Pathol 9 707 720 10517509 1:CAS:528:DyaK1MXmvV2ntb8%3D (Pubitemid 29470963)
58. B Herting S Schulze H Reichmann A Haehner T Hummel 2008 A longitudinal study of olfactory function in patients with idiopathic Parkinson's disease J Neurol 255 367 370 18343969
59. EC Hirsch 2006 Altered regulation of iron transport and storage in Parkinson's disease J Neural Transm Suppl 71 201 204 17447430 1:CAS:528:DC%2BD28Xht1OltLbM (Pubitemid 351412121)
60. JJ Hoozemans ES van Haastert P Eikelenboom RA de Vos JM Rozemuller W Scheper 2007 Activation of the unfolded protein response in Parkinson's disease Biochem Biophys Res Commun 354 707 711 17254549 1:CAS:528:DC%2BD2sXhtlOgu74%3D (Pubitemid 46186242)
61. PS Hubbard MM Esiri M Reading R McShane Z Nagy 2007 α-synuclein pathology in the olfactory pathways of dementia patients J Anat 211 117 124 17553102 (Pubitemid 47034515)
62. A Iranzo JL Molinuevo J Santamaria M Serradell MJ Marti F Vallderiola E Tolosa 2006 Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study Lancet Neurol 5 572 577 16781987 (Pubitemid 43867426)
63. A Ishii T Nonaka S Taniguchi T Saito T Arai D Mann T Iwatsubo S Hisanaga M Goedert M Hasegawa 2007 Casein kinase 2 is the major enzyme in brain that phosphorylates Ser129 of human alpha-synuclein: implication for alpha-synucleinopathies FEBS Lett 581 4711 4717 17868672 1:CAS:528: DC%2BD2sXhtVOltrzN (Pubitemid 47418797)
64. K Iwanaga K Wakabayashi M Yoshimoto I Tomita H Satoh H Takashima M Satoh M Tsujihara H Takahashi 1999 Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body disease Neurology 52 1269 1271 10214756 1:STN:280:DyaK1M3ivFGluw%3D%3D (Pubitemid 29177934)
65. KA Jellinger 2004 Lewy body-related synucleinopathy in the aged human brain J Neural Transm 111 1219 1235 15480835 1:CAS:528:DC%2BD2cXotFCrtbk%3D (Pubitemid 39468387)
66. KA Jellinger 2008 A critical reappraisal of current staging of Lewy-related pathology in human brain Acta Neuropathol 116 1 16 18592254 1:CAS:528:DC%2BD1cXosVOjtbw%3D
67. KA Jellinger 2009 A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders Biochim Biophys Acta 1792 730 740 18718530 1:CAS:528:DC%2BD1MXnsFygs7k%3D
68. KA Jellinger 2010 Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases Neurodegener Dis 7 112 115 20173339 1:CAS:528:DC%2BC3cXks1KjtL4%3D
69. Jellinger K, Mizuno Y (2003) Parkinson's disease. In: Dickson D (ed) Neurodegeneration: the molecular pathology of dementia and movement disorders. ISN Neuropathol Press, Bassel, pp 159-187
70. P Jenner 1993 Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease Acta Neurol Scand Suppl 146 6 13 8333254 1:STN:280:DyaK3szisFelsg%3D%3D (Pubitemid 23251601)
71. P Jenner 1998 Oxidative mechanisms in nigral cell death in Parkinson's disease Mov Disord 13 24 34 9613715
72. P Jenner DT Dexter J Sian AH Schapira CD Marsden 1992 Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group Ann Neurol 32 S82 S87 1510385 1:CAS:528:DyaK3sXnvVSntQ%3D%3D
73. PM Keeney J Xie RA Capaldi JP Bennett 2006 Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled J Neurosci 26 5256 5264 16687518 1:CAS:528: DC%2BD28Xlt1Cisrk%3D (Pubitemid 44315308)
74. AE Kingsbury SE Daniel H Sangha S Eisen AJ Lees OJ Foster 2004 Alteration in alpha-synuclein mRNA expression in Parkinson's disease Mov Disord 19 162 170 14978671 (Pubitemid 38312698)
75. DJ Klionsky H Abeliovich P Agostinis DK Agrawal G Aliev DS Askew, et al. 2008 Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes Autophagy 4 151 175 18188003 1:CAS:528: DC%2BD1cXksFGrtLg%3D (Pubitemid 351231180)
76. D Koziorowski A Friedman P Arosio P Santambrogio D Dziewulska 2007 ELISA reveals a difference in the structure of substantia nigra ferritin in Parkinson's disease and incidental Lewy body compared to control Parkinsonism Relat Disord 13 214 218 17275395 (Pubitemid 46603035)
77. E Kuusisto L Parkkinen I Alafuzoff 2003 Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62 J Neuropathol Exp Neurol 62 1241 1253 14692700 1:CAS:528:DC%2BD2cXht1Onsw%3D%3D (Pubitemid 37494193)
78. JB Leverenz I Umar Q Wang TJ Montine PJ McMillan DW Tsuang J Jin C Pan J Shin D Zhu J Zhang 2007 Proteomic identification of novel proteins in cortical Lewy bodies Brain Pathol 17 139 145 17388944 1:CAS:528:DC%2BD2sXls12rsrY%3D (Pubitemid 46466133)
79. W Li N West E Colla O Pletnikova JC Troncoso L Marsh TM Dawson P Jakala T Hartmann DL Price MK Lee 2005 Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations Proc Natl Acad Sci USA 102 2162 2167 15684072 1:CAS:528:DC%2BD2MXhvFGqs7g%3D (Pubitemid 40262029)
80. SK Mak AL McCormack AB Manning-Bog AM Cuervo DA Di Monte 2010 Lysosomal degradation of α-synuclein in vivo J Biol Chem 285 13621 13629 20200163 1:CAS:528:DC%2BC3cXltFOgsb8%3D
81. WR Markesbery GA Jicha H Liu FA Schmitt 2009 Lewy body pathology in normal elderly subjects J Neuropathol Exp Neurol 68 816 822 19535990
82. A Martínez M Portero-Otin R Pamplona I Ferrer 2010 Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates Brain Pathol 20 281 297 19725834
83. M Martínez-Vicente Z Talloczy S Kaushik AC Massey J Mazzulli EV Mosharov R Hodara R Fredenburg DC Wu A Follenzi W Dauer S Przedborski H Ischiropoulos PT Lansbury D Sulzer AM Cuervo 2008 Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy J Clin Invest 118 777 788 18172548
84. S Matsuda M Okano K Yamagishi M Nagao M Ueda R Sasaki 1994 A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes J Biol Chem 269 19488 19493
85. A McKinlay RC Grace JC Dalrymple-Alford D Roger 2009 Cognitive characteristics associated with mild cognitive impairment in Parkinson's disease Dement Geriatr Cogn Disord 28 121 129 19690414 1:STN:280:DC%2BD1MnhtVSntQ%3D%3D
86. Y Mizuno S Ohta M Tanaka S Takamiya K Suzuki T Sato H Oya T Ozawa Y Kagawa 1989 Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease Biochem Biophys Res Commun 163 1450 1455 2551290 1:CAS:528:DyaL1MXmtFarsLg%3D (Pubitemid 19244751)
87. Muntané G, Ferrer I, Martínez-Vicente M α-Synuclein phosphorylation and lysosomal-mediated α-synuclein truncation are normal events in the adult human brain (in preparation)
88. G Muntané E Dalfó A Martinez I Ferrer 2008 Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related α-synucleinopathies Neuroscience 152 913 923 18343584
89. IV Murray BI Giasson SM Quinn V Koppaka PH Axelsen H Ischiropoulos JQ Trojanowski VM Lee 2003 Role of alpha-synuclein carboxy-terminus on fibril formation in vitro Biochemistry 42 8530 8540 12859200 1:CAS:528: DC%2BD3sXkvVaitbw%3D (Pubitemid 36875420)
90. K Nakaso Y Yoshimoto T Nakano T Takeshima Y Fukuhara K Yasui S Araga T Yanagawa T Ishii K Nakashima 2004 Transcriptional activation of p62/A170/ZIP during the formation of the aggregates: possible mechanisms and the role in Lewy body formation in Parkinson's disease Brain Res 1012 42 51 15158159 1:CAS:528:DC%2BD2cXktF2ltLg%3D (Pubitemid 38648897)
91. G Natale L Pasquali S Riuggieri A Paparelli F Fornai 2008 Parkinson's disease and the gut: a well known clinical association in need of an effective cure and explanation Neurogastroenterol Motil 20 741 749 18557892 1:CAS:528:DC%2BD1cXovFSnu7s%3D (Pubitemid 351814395)
92. A Navarro A Boveris MJ Bández MJ Sánchez-Pino C Gómez G Muntané I Ferrer 2009 Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies Free Radic Biol Med 46 1574 1580 19298851 1:CAS:528: DC%2BD1MXlslWlt7s%3D
93. AE Oakley JF Collingwood J Dobson G Love HR Perrott JA Edwardson M Elstner CM Morris 2007 Individual dopaminergic neurons show raised iron levels in Parkinson disease Neurology 68 1820 1825 17515544 1:STN:280: DC%2BD2szgsVynuw%3D%3D (Pubitemid 46791395)
94. CW Olanow KS McNaught 2006 Ubiquitin-proteasome system and Parkinson's disease Mov Disord 21 1806 1823 16972273 (Pubitemid 44856478)
95. IG Onyango 2008 Mitochondrial dysfunction and oxidative stress in Parkinson's disease Neurochem Res 33 589 597 17940895 1:CAS:528: DC%2BD1cXhs1aiu70%3D (Pubitemid 351230462)
96. T Pan S Kondo W Le J Jankovic 2008 The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson's disease Brain 131 1969 1978 18187492
97. WD Parker SJ Boyson JK Parks 1989 Abnormalities of the electron transport chain in idiopathic Parkinson's disease Ann Neurol 26 719 723 2557792 (Pubitemid 20011004)
98. L Parkkinen T Kauppinen T Pirttilä JM Autere I Alafuzoff 2005 α-Synuclein pathology does not predict extrapyramidal symptoms or dementia Ann Neurol 57 82 91 15562510 1:CAS:528:DC%2BD2MXpsFSktQ%3D%3D (Pubitemid 40053318)
99. L Parkkinen T Pirttilä I Alafuzoff 2008 Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance Acta Neuropathol 115 399 407 18297293
100. RK Pearce CH Hawkes SE Daniel 1995 The anterior olfactory nucleus in Parkinson's disease Mov Disord 10 283 287 7651444 1:STN:280:DyaK2MznvFyktg%3D%3D
101. KF Pedersen G Alves D Aarsland JP Larsen 2009 Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study J Neurol Neurosurg Psychiatry 80 1279 1782 19864662 1:STN:280: DC%2BD1Mjit1Ogsg%3D%3D
102. W Poewe 2007 Dysautonomia and cognitive dysfunction in Parkinson's disease Mov Disord Suppl 17 S374 S378
103. W Poewe 2008 Non-motor symptoms in Parkinson's disease Eur J Neurol 15 Suppl 1 14 20 18353132 (Pubitemid 351421304)
104. RB Postuma AE Lang J Massicotte-Marquez J Montplaisir 2006 Potential early markers of Parkinson disease in idiopathic REM sleep behavioral disorder Neurology 66 845 851 16567700 1:CAS:528:DC%2BD28XitFOiuro%3D (Pubitemid 43739758)
105. F Richter BH Meurers C Zhu VP Medvedeva 2009 Neurons express haemoglobin α- and β-chains in rat and human brains J Comp Neurol 515 538 547 19479992 1:CAS:528:DC%2BD1MXos1yjtLs%3D
106. E Rockenstein LA Hansen M Mallory JQ Trojanowski D Galasko E Masliah 2001 Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease Brain Res 914 48 56 11578596 1:CAS:528:DC%2BD3MXntV2js74%3D (Pubitemid 32905430)
107. GW Ross H Petrovitch RD Abbott CM Tanner J Popper K Masaki L Launer LR White 2008 Association of olfactory dysfunction with risk for future Parkinson's disease Ann Neurol 63 167 173 18067173 (Pubitemid 351355295)
108. MY Ryu DW Kim K Arima MM Mouradian SU Kim G Lee 2008 Localization of CKII beta subunits in Lewy bodies of Parkinson's disease J Neurol Sci 266 9 12 17884098 1:CAS:528:DC%2BD1cXhslGhsrk%3D (Pubitemid 351186510)
109. Y Saito NN Ruberu M Sawabe T Arai H Kazama T Hosoi H Yamanouchi S Murayama 2004 Lewy body-related α-synucleinopathy in aging J Neuropathol Exp Neurol 63 742 749 15290899
110. J Salazar N Mena MT Núñez 2006 Iron dyshomeostasis in Parkinson's disease J Neural Transm Suppl 71 205 213 17447431 1:CAS:528:DC%2BD28Xht1OltLbN (Pubitemid 351412122)
111. AH Schapira 2008 Mitochondria in the aetiology and pathogenesis of Parkinson's disease Lancet Neurol 7 97 109 18093566 1:CAS:528: DC%2BD1cXhtlaqtbg%3D (Pubitemid 350251942)
112. CW Schults 2006 Lewy bodies Proc Nat Acad Sci USA 103 1661 1668
113. M Shamoto-Nagai W Maruyama Y Hashizume M Yoshida T Osawa P Riederer M Naoi 2007 In parkinsonian substantia nigra, α-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of the proteasome activity J Neural Transm 114 1559 1567 17690948 1:CAS:528:DC%2BD2sXhtlOru77K (Pubitemid 350212012)
114. A Siderowf MB Stern 2008 Premotor Parkinson's disease: clinical features, detection, and prospects for treatment Ann Neurol 64 Suppl 2 S139 S147 19127581
115. SM Solano DW Miller SJ Augood AB Young JB Penney Jr 2000 Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson's disease Ann Neurol 47 201 210 10665491 1:CAS:528:DC%2BD3cXhtV2mtrk%3D (Pubitemid 30078567)
116. MG Spillantini M Schmidt VM Lee JQ Trojanowski R Kaques M Goedert 1997 α-Synuclein in Lewy bodies Nature 388 839 840 9278044 1:CAS:528: DyaK2sXlslWru7o%3D
117. G Srivastava K Singh MN Tiwari MP Singh 2010 Proteomics in Parkinson's disease: current trends, translational snags and future possibilities Expert Rev Proteomics 7 127 139 20121482 1:CAS:528:DC%2BC3cXhtlOitbw%3D
118. L Stefanis KE Larsen HJ Rideout D Sulzer LA Greene 2001 Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death J Neurosci 21 9549 9560 11739566 1:CAS:528:DC%2BD38XivV2i (Pubitemid 34184043)
119. K Stiasny-Kolster Y Doerr JC Möller H Höffken TM Behr WH Oertel G Mayer 2005 Combination of idiopathic REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT Brain 128 126 137 15548552 1:STN:280:DC%2BD2cnit1eguw%3D%3D (Pubitemid 40070527)
120. CC Tang KL Poston V Dhawan D Eidelberg 2010 Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease J Neurosci 30 1049 1056 20089913 1:CAS:528:DC%2BC3cXhtlKmurc%3D
121. E Tolosa Y Compta C Gaig 2007 The premotor phase of Parkinson's disease Parkinsonism Rel Disord 13 S2 S7
122. F Tribl K Marcus HE Meyer G Bringmann M Gerlach P Riederer 2006 Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle J Neural Transm 113 741 749 16755378 1:CAS:528:DC%2BD28XltlGlt7Y%3D (Pubitemid 43847167)
123. F Tribl E Asan T Arzberger T Tatschner E Langenfeld HE Meyer G Bringmann P Riederer M Gerlach K Marcus 2009 Identification of L-ferritin in neuromelanin granules of the human substantia nigra: a targeted proteomics approach Mol Cell Proteomics 8 1832 1838 19318681 1:CAS:528:DC%2BD1MXhtVSjtbvL
124. K Varani F Vincenzi A Tosi S Gessi I Casetta G Granieri P Fazio E Leung S MacLennan E Granieri PA Borea 2010 A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease FASEB J 24 587 598 19776336 1:CAS:528:DC%2BC3cXhs1Ggsro%3D
125. T Vogiatzi M Xilouri K Vekrellis L Stefanis 2008 Wild type α-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells J Biol Chem 283 23542 23556 18566453 1:CAS:528: DC%2BD1cXhtVWksbfE
126. K Wakabayashi K Matsumoto K Takayama M Yoshimoto H Takahashi 1997 NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease Neurosci Lett 249 180 182
127. K Wakabayashi K Tanji F Mori H Takahashi 2007 The Lewy body in Parkinson's disease: molecules implicated in the formation and degradation of α-synuclein aggregates Neuropathology 27 494 506 18018486 (Pubitemid 47459715)
128. HQ Wang R Takahashi 2007 Expanding insights on the involvement of endoplasmic reticulum stress in Parkinson's disease Antioxid Redox Signal 9 553 561 17465880 1:CAS:528:DC%2BD2sXktFCit74%3D (Pubitemid 46598253)
129. R Wang H Qing XQ Liu XL Zheng YL Deng 2008 Iron contributes to the formation of catechol isoquinolines and oxidative toxicity induced by overdose dopamine in dopaminergic SH-SY5Y cells Neurosci Bull 24 125 132 18500384 1:CAS:528:DC%2BD1MXntFOlsrs%3D (Pubitemid 352020325)
130. EA Waxman BI Giasson 2008 Specificity and regulation of casein kinase-mediated phosphorylation of alpha-synuclein J Neuropathol Exp Neurol 67 402 416 18451726 1:CAS:528:DC%2BD1cXmsFehtbg%3D (Pubitemid 351653529)
131. D Weisman M Cho C Taylor A Adame LJ Thal LA Hansen 2007 In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution Neurology 69 356 359 17646627 1:STN:280:DC%2BD2svislGrtA%3D%3D (Pubitemid 47205662)
132. K Wirdefeldt N Bogdanovic L Westerberg H Payami M Schalling G Murdoch 2001 Expression of alpha-synuclein in the human brain: relation to Lewy body disease Brain Res Mol Brain Res 92 58 65 11483242 1:CAS:528:DC%2BD3MXls1aqtL4%3D (Pubitemid 32718705)
133. A Wypijewska J Galazka-Friedman ER Bauminger ZK Wszolek KJ Schweitzer DW Dickson A Jaklewicz D Elbaum A Friedman 2010 Iron and reactive oxygen species activity in parkinsonian substantia nigra Parkinsonism Relat Disord 16 329 333 20219408
134. Q Xia L Liao D Cheng DM Duong M Gearing JJ Lah AI Levey J Peng 2008 Proteomic identification of novel proteins associated with Lewy bodies Front Biosci 13 3850 3856 18508479 1:CAS:528:DC%2BD1cXnsVKqtb0%3D (Pubitemid 351594664)
135. M Xilouri T Vogiatzi K Vekrellis L Stefanis 2008 alpha-synuclein degradation by autophagic pathways: a potential key to Parkinson's disease pathogenesis Autophagy 4 917 919 18708765 1:CAS:528:DC%2BD1cXht12rurjM
136. MB Youdim 2008 Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus Neurotox Res 14 45 56 18790724 1:CAS:528:DC%2BD1MXpsFWqtA%3D%3D
137. L Zecca FA Lucca A Albertini E Rizzio RG Fariello 2006 A proposed dual role of neuromelanin in the pathogenesis of Parkinson disease Neurology 67 Suppl 2 S8 S11 17030740 1:CAS:528:DC%2BD28XhtVeqsLfJ
138. L Zecca L Casella A Albertini C Bellei FA Zucca M Engelen A Zadlo G Szewczyk M Zareba T Sarna 2008 Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease J Neurochem 106 1866 1875 18624918 1:CAS:528:DC%2BD1cXhtVegtLjK
139. GD Zeevalk R Razmpour LP Bernard 2008 Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62 236 249 18400456 1:CAS:528:DC%2BD1cXls1Sisb0%3D (Pubitemid 351626446)
140. T Ziemssen H Reichmann 2007 Non-motor dysfunction in Parkinson's disease Parkinsonism Rel Disord 13 323 332 (Pubitemid 47212791)